PCM
UPB

Prelude Capital Management’s Upstream Bio Inc UPB Stock Holding History

Prelude Capital Management’s Portfolio UPB Stock Details UPB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,560
Closed -$450K – 1661
2025
Q4 		$450K Buy
16,560
+825
+5% +$20.5K 0.03% 586
2025
Q3 		$296K Buy
+15,735
New +$244K 0.02% 736

Other funds holding UPB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Prelude Capital Management's UPB Position: Q1 2026 in Review

Prelude Capital Management sold out of Upstream Bio Inc (UPB) in Q1 2026, closing a stake of 16,560 shares — an estimated $450K sold.

Prelude Capital Management first reported a position in UPB in Q3 2025 and held it in 2 quarters. The position peaked at $450K in Q4 2025. 140 funds tracked by Wall St. Rank hold UPB as of Q1 2026.

  • Prelude Capital Management reported no remaining Upstream Bio Inc position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 16,560 Upstream Bio Inc shares in Q1 2026, an estimated $450K.
  • Prelude Capital Management first reported a position in Upstream Bio Inc in Q3 2025 and held it in 2 quarters.
  • Prelude Capital Management's Upstream Bio Inc position peaked at $450K in Q4 2025.
  • 140 funds tracked by Wall St. Rank held Upstream Bio Inc as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.